Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Comment by Alex1100on May 08, 2020 1:50pm
143 Views
Post# 31004303

RE:Disappointing

RE:DisappointingKingbear, thanks for your good post - finally someone who can think!
I have posted yesterday on other board as follows:

Three years ago, on today day, Aphria s/p was almost identical to its current (today) price. Bearing in mind gradual opening of the European and Asian economies, and fact that the new investment cycle is inevitable, I wonder the following: How many investors would like to invest in a sound company that promised a lot and fulfilled even more, but also in the company whose s/p has not moved for a cent after three years? How many serious investors will invest in Aphria in the midst of a bunch of good companies that are currently severely undervalued due to the pandemic, but whose performance has been proven many times before? I suspect very few! If those investors weren't interested in Aphria when the company showed the most resilience in the toughest of times, why would they be interested after?

I seem to know the answer to those questions, though I'd love to hear it from you as well. I will risk repeating myself by saying what I have tried to articulate several times on this board, which is that the answer, I hereby only speculate, lies in the marriage of convenience between Aphria and some large financial institutions. Unfortunately, this marriage has been very successful so far - it has brought a lot of money and satisfaction to the partners and this is why it is still lasting. Serious investors, of course, know this and don't want to be "third in bed", so, I am speculating again, this is the only reason we still do not see serious demand for Apha that would eventually separate us from CGC and propel the company to the place it deserves.

<< Previous
Bullboard Posts
Next >>